McIlrath & Eck’s AstraZeneca AZN Stock Holding History

McIlrath & Eck’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.81K	Sell	30 -1	-3%	-$193	﹤0.01%	1183
2025 Q4	$5.61K	Hold	31	–	–	﹤0.01%	758
2025 Q3	$4.68K	Hold	31	–	–	﹤0.01%	755
2025 Q2	$4.26K	Hold	31	–	–	﹤0.01%	745
2025 Q1	$4.48K	Hold	31	–	–	﹤0.01%	738
2024 Q4	$4K	Hold	31	–	–	﹤0.01%	791
2024 Q3	$4.75K	Hold	31	–	–	﹤0.01%	747
2024 Q2	$4.76K	Hold	31	–	–	﹤0.01%	721
2024 Q1	$4.13K	Hold	31	–	–	﹤0.01%	755
2023 Q4	$4.11K	Hold	31	–	–	﹤0.01%	712
2023 Q3	$4.13K	Hold	31	–	–	﹤0.01%	690
2023 Q2	$4.37K	Sell	31 -698	-96%	-$103K	﹤0.01%	699
2023 Q1	$101K	Hold	729	–	–	0.02%	157
2022 Q4	$98.8K	Hold	729	–	–	0.03%	151
2022 Q3	$80K	Hold	729	–	–	0.02%	177
2022 Q2	$96K	Hold	729	–	–	0.03%	139
2022 Q1	$97K	Hold	729	–	–	0.03%	145
2021 Q4	$85K	Hold	729	–	–	0.02%	169
2021 Q3	$88K	Buy	729 +585	+406%	+$68.1K	0.03%	155
2021 Q2	$17K	Hold	144	–	–	0.01%	418
2021 Q1	$14K	Hold	144	–	–	﹤0.01%	411
2020 Q4	$14K	Hold	144	–	–	0.01%	354
2020 Q3	$16K	Hold	144	–	–	0.01%	296
2020 Q2	$15K	Buy	144 +30	+26%	+$3.1K	0.01%	283
2020 Q1	$10K	Hold	114	–	–	0.01%	302
2019 Q4	$11K	Hold	114	–	–	0.01%	345
2019 Q3	$10K	Hold	114	–	–	0.01%	336
2019 Q2	$9K	Hold	114	–	–	0.01%	350
2019 Q1	$9K	Buy	+114	New	+$8.99K	0.01%	350

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

McIlrath & Eck's AZN Position: Q1 2026 in Review

McIlrath & Eck reduced its AstraZeneca (AZN) stake by 3.2% in Q1 2026, selling an estimated $193 and leaving 30 shares worth $5.81K. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

McIlrath & Eck first reported a position in AZN in Q1 2019 and has held it in 29 quarters since. The position peaked at $101K in Q1 2023. 1,386 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

McIlrath & Eck held 30 shares of AstraZeneca worth $5.81K as of Q1 2026.
McIlrath & Eck sold 1 AstraZeneca share in Q1 2026, an estimated $193.
AstraZeneca made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1183 holding.
McIlrath & Eck first reported a position in AstraZeneca in Q1 2019 and has held it in 29 quarters since.
McIlrath & Eck's AstraZeneca position peaked at $101K in Q1 2023.
1,386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.